(E)-3-hydroxy-N′-(2-hydroxybenzylidene)-2-naphthohydrazide | 80648-84-6

• 物质功能分类: 分析化学 - 分析试剂 - 常用分析试剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (E)-3-hydroxy-N′-(2-hydroxybenzylidene)-2-naphthohydrazide
• 英文别名: 3-hydroxy-2-naphthoyl hydrazone of salicylaldehyde；(E)-3-hydroxy-N'-(2-hydroxybenzylidene)-2-naphthohydrazide；3-hydroxy-[2]naphthoic acid salicylidenehydrazide；3-Hydroxy-[2]naphthoesaeure-salicylidenhydrazid；Salicylaldehyde (3-hydroxy-2-naphthoyl)hydrazone；3-hydroxy-N-[(E)-(2-hydroxyphenyl)methylideneamino]naphthalene-2-carboxamide
• CAS: 80648-84-6
• 化学式: C₁₈H₁₄N₂O₃
• 分子量: 306.321
• InChiKey: XTQAGBABCDSRSN-YBFXNURJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-3-hydroxy-N′-(2-hydroxybenzylidene)-2-naphthohydrazide 、 copper diacetate 以 甲醇 、 乙醇 为溶剂， 生成 Cu(3-hydroxy-2-naphthoyl hydrazone of salicylaldehyde)
  参考文献：
  名称：

  Osman, M. M.; Ali, G. Y., Acta Chimica Academiae Scientiarum Hungaricae, 1981, vol. 108, # 1, p. 13 - 24

  摘要：

  DOI：
• 作为产物：
  描述：

  2-羟基-3-萘甲酸 在 盐酸 、 一水合肼 作用下， 以 乙醇 、 水 为溶剂， 反应 6.25h， 生成 (E)-3-hydroxy-N′-(2-hydroxybenzylidene)-2-naphthohydrazide
  参考文献：
  名称：

  Structure–Activity Relationships in Non-Ligand Binding Pocket (Non-LBP) Diarylhydrazide Antiandrogens

  摘要：

  We report the synthesis and a study of the structure activity relationships of a new series of diarylhydrazides as potential selective non-ligand binding pocket androgen receptor antagonists. Their biological activity as antiandrogens in the context of the development of treatments for castration resistant prostate cancer was evaluated using in vitro time resolved fluorescence resonance energy transfer and fluorescence polarization on target assays. Additionally, a theoretical study combining docking and molecular dynamics methods was performed to provide insight into their mechanism of action as a basis for further lead optimization studies.

  DOI：

  10.1021/ci400189m

文献信息

• BATE-LACTAMASE INHIBITORS
  申请人：Dmitrienko Gary I.

  公开号：US20110046101A1

  公开（公告）日：2011-02-24

  The present invention relates to broad spectrum β-lactamase inhibitors. More particularly, the invention relates to inhibitors of Class B metallo (MBL) and Class D (OXA) β-lactamases. A method of treating a bacterial infection is provided, wherein the method comprises administering to a mammalian patient in need of such treatment a compound of formula (I) wherein R 1 is selected from R 2 is selected from with certain provisos as herein defined; in combination with a pharmaceutically acceptable β-lactam antibiotic in an amount which is effective for treating the bacterial infection.

  本发明涉及广谱β-内酰胺酶抑制剂。更具体地，本发明涉及类B金属酶(MBL)和类D（OXA）β-内酰胺酶的抑制剂。提供了一种治疗细菌感染的方法，其中该方法包括向需要此类治疗的哺乳动物患者施用具有以下结构的化合物（I）其中R1从中选择R2从中选择与此处定义的某些条件一起；与一种对治疗细菌感染有效的药用β-内酰胺抗生素结合在一起。
• Toward the discovery of dual inhibitors for botulinum neurotoxin A: concomitant targeting of endocytosis and light chain protease activity
  作者：Hajime Seki、Song Xue、Mark S. Hixon、Sabine Pellett、Marek Remes̆、Eric A. Johnson、Kim D. Janda

  DOI：10.1039/c5cc00677e

  日期：——

  A polypharmacological approach as a treatment for botulinum neurotoxin A intoxication is presented.

  提出了一种多药理学方法作为治疗肉毒杆菌神经毒素A中毒的方法。
• Homogeneous green catalysts for olefin oxidation by mono oxovanadium(V) complexes of hydrazone Schiff base ligands
  作者：Hassan Hosseini Monfared、Rahman Bikas、Peter Mayer

  DOI：10.1016/j.ica.2010.04.046

  日期：2010.8

  Three mono oxovanadium(V) complexes of tridentate Schiff base ligands [VO(OMe)L-1] (1), [VO(OMe)L-2] (2) and [VO(OMe)L-3] (3) obtained by monocondensation of 3-hydroxy-2-naphthohydrazide and aromatic o-hydroxyaldehydes have been synthesized (H2L1 = (E)-3-hydroxy-N '-(2-hydroxy-3-methoxybenzylidene)- 2-naphthohydrazide, H2L2 = (E)-3-hydroxy-N '-(2-hydroxybenzylidene)-2-naphthohydrazide and H2L3 = (E)-N '-(5-bromo-2-hydroxybenzylidene)-3-hydroxy-2-naphthohydrazide). The complexes were characterized by spectroscopic methods in the solid state (IR) and in solution (UV-Vis, H-1 NMR). Single crystal X-ray analyses were performed with 1 and 2. The catalytic potential of these complexes has been tested for the oxidation of cyclooctene using H2O2 as the terminal oxidant. The effects of various parameters including the molar ratio of oxidant to substrate, the temperature, and the solvent have been studied. The catalyst 2 showed the most powerful catalytic activity in oxidation of various terminal, cyclic and phenyl substituted olefins. Excellent conversions have been obtained for the oxidation of cyclic and bicyclic olefins. (C) 2010 Elsevier B.V. All rights reserved.
• ANDROGEN RECEPTOR LIGANDS
  申请人：Lloyd David George

  公开号：US20140357682A1

  公开（公告）日：2014-12-04

  Non ligand binding pocket antagonists for the human androgen receptor. The androgen receptor (AR) is a member of the Nuclear Receptor (NR) family and its role is to modulate the biological effects of the endogenous androgens, testosterone (tes) and dihydrotestosterone (DHT). Synthetic androgens and anti-androgens have therapeutic value in the treatment of various androgen dependent conditions, from regulation of male fertility to prostate cancer. Current treatment of prostate cancer (PCa) typically involves administration of ‘classical’ antiandrogens, competitive inhibitors of natural AR ligands, DHT and tes, for the ligand binding pocket (LBP) in the C-terminal ligand binding domain (LBD) of the AR. However, prolonged LBP-targeting can often lead to androgen resistance and alternative therapies and therapeutic strategies are urgently required. Disclosed herein are a class of non-steroidal, small molecule AR antagonists which inhibit the transcriptional activity of the AR by non LBP-mediated modulation. The novel class reported demonstrates full (‘true’) antagonism in AR with low micromolar potency, high selectivity over both the Estrogen Receptors alpha and beta (ERα and ERβ) and the Glucocorticoid Receptor (GR) and only micromolar partial antagonism in the Progesterone Receptor (PR). Data provide compelling evidence for such non-LBP intervention as an alternative approach to classical PCa therapy. (Formula I).
• MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT
  申请人：The University of Kansas

  公开号：US20170144965A1

  公开（公告）日：2017-05-25

  A pharmaceutical composition can include: a marmelin analog compound, and a pharmaceutically acceptable carrier having the compound. The compound can be present in a therapeutically effective amount to treat or inhibit a disease state. The disease state can be cancer. The cancer can be selected from brain cancers, head and neck cancers, thyroid cancers, gastrointestinal cancers, esophageal cancers, stomach cancers, pancreatic cancers, liver cancers, colo-rectal cancers, lung cancers, kidney cancers, prostate cancers, bladder cancers, testicular cancers, breast cancers, ovarian cancers, cervical cancers, and melanomas. The carrier includes a cyclodextrin, which may form a complex with the compound. The compounds and compositions can be used to treat or inhibit progression of cancers. Colorectal, bladder, and prostate cancers are examples of some of the cancers that can be treated with the marmelin analog compounds.